COMPONENTA FG (CLP)

Land: Irland

Språk: engelska

Källa: Ecolab

Tillgänglig från:

ECOLAB DEUTSCHLAND GMBH

Säkerhetsdatablad

SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006
COMPONENTA FG
116076E
1 / 11
SECTION: 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE
COMPANY/UNDERTAKING
1.1 PRODUCT IDENTIFIER
Product name
:
Componenta FG
UFI
:
FSNM-5QFK-F901-AP8P
Product code
:
116076E
Use of the
Substance/Mixture
:
Defoamer
Substance type:
:
Mixture
FOR PROFESSIONAL USERS ONLY.
Product dilution information
:
No dilution information provided.
1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE OR MIXTURE AND USES
ADVISED AGAINST
Identified uses
:
Defoaming product. Automatic process
Recommended restrictions
on use
:
Reserved for industrial and professional use.
1.3 DETAILS OF THE SUPPLIER OF THE SAFETY DATA SHEET
Company
:
Ecolab Limited
Forest Park
Mullingar Industrial Estate, Mullingar Co. Westmeath Ireland +353
1 276 3500
[e-mail]
Ecolab Ltd.
PO Box 11; Winnington Avenue
Northwich, Cheshire, United Kingdom CW8 4DX
[phone]
[e-mail]
1.4 EMERGENCY TELEPHONE NUMBER
Poison Information Centre
telephone number
:
For medical professionals only:
[phone] (8am - 10pm, every day of the week)
Date of Compilation/Revision
:
20.12.2021
version
:
1.4
SECTION: 2. HAZARDS IDENTIFICATION
2.1 CLASSIFICATION OF THE SUBSTANCE OR MIXTURE
CLASSIFICATION (REGULATION (EC) NO 1272/2008)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006
COMPONENTA FG
116076E
2 / 11
Not a hazardous substance or mixture.
2.2 LABEL ELEMENTS
LABELLING (REGULATION (EC) NO 1272/2008)
Not a hazardous substance or mixture.
2.3 OTHER HAZARDS
None known.
SECTION: 3. COMPOSITION/INFORMATION ON INGREDIENTS
3.2 MIXTURES
Remarks
:
No hazardous ingredients
SECTION: 4. FIRST AID MEASURES
4.1 DESCRIPTION OF FIRST AID MEASURES
In case of eye contact
:
Rinse with plenty of water.
In case of skin contact
:
Rinse with plenty of water.
If swallowed
:
Rinse mouth. Get medical attention if symptoms occur.
If inhaled
:
Get medical attention if symptoms occur.
4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED
See Section 11 for more de